Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.
Type:
Grant
Filed:
September 27, 2004
Date of Patent:
March 10, 2009
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Christoph Reinhard, Anne B. Jefferson, Vivien W. Chan
Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.
Type:
Grant
Filed:
September 27, 2004
Date of Patent:
March 10, 2009
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Christoph Reinhard, Anne B. Jefferson, Vivien W. Chan
Abstract: The present invention provides methods for identification of cancerous cells by detection of expression levels of TTK, as well as diagnostic, prognostic and therapeutic methods that take advantage of the differential expression of these genes in mammalian cancer. Such methods can be useful in determining the ability of a subject to respond to a particular therapy, e.g., as the basis of rational therapy. In addition, the invention provides assays for identifying pharmaceuticals that modulate activity of these genes in cancers in which these genes are involved, as well as methods of inhibiting tumor growth by inhibiting activity of TTK.
Type:
Grant
Filed:
September 27, 2004
Date of Patent:
March 10, 2009
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Christoph Reinhard, Anne B. Jefferson, Vivien W. Chan
Abstract: Methods and apparatus are disclosed for automatically setting an X-Ray strength based at least in part on the volume of an object. Lasers are used to measure distances to the object. Using the measured distances, a volume of the object to be X-Rayed is estimated. Using the estimated volume, an appropriate X-Ray strength is determined and an X-Ray machine is adjusted to provide X-Rays of that strength.
Abstract: A system and method are provided for optimizing the amount of radiation exposure to a patient. The system and method comprise inputting a set of parameters based on characteristics of the patient, positioning components of a medical imaging equipment, comparing the input parameters and position of the components to computed optimum parameters and positions, and providing an indication of an amount of radiation dosage to be dispensed based on at least one of the input parameters and the position of the components.
Abstract: The present invention provides a compound of Formula (I) or a pharmaceutically acceptable salt thereof; pharmaceutical compositions comprising an effective amount of a compound of Formula I in combination with a suitable carrier, diluent, or excipient; and methods for treating physiological disorders, particularly congestive heart disease, hypertension, rheumatoid arthritis or inflammation, comprising administering to a patient in thereof an effective amount of a compound of Formula (I).
Type:
Grant
Filed:
December 15, 2004
Date of Patent:
January 27, 2009
Assignee:
Eli Lilly and Company
Inventors:
Michael Joseph Coghlan, Prabhakar Kondaji Jadhav, James Joseph Droste, Jonathan Edward Green, Donald Paul Matthews
Abstract: This invention relates to compositions and uses of NRG4, and to variants thereof and to polynucleotides encoding NRG4, for therapeutic and diagnostic purposes, particularly related to colon and pancreatic cancer. This invention also relates to therapeutic agents based on or derived from the polynucleotides and proteins, NRG4 inhibitors, particularly antibodies capable of specifically binding to NRG4.
Type:
Grant
Filed:
February 9, 2007
Date of Patent:
January 13, 2009
Assignee:
Novartis Vaccines and Diagnostics, Inc.
Inventors:
Siew C. Schleyer, Anne B. Jefferson, Judith A. Abraham, W. Michael Kavanaugh